Combination therapy for treating malignancies

Inventors

AGRESTA, Samuel V.

Assignees

Servier Pharmaceuticals LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11419859-B2

Patent

Publication Date

2022-08-23

Expiration Date


Abstract

Provided are methods and compositions for treating acute myelogenous leukemia (AML) in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme, (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide in combination with cytarabine and doxorubicin or idarubicin as an induction therapy and either cytarabine or a combination of combination of mitoxantrone and etoposide as consolidation therapy.

Core Innovation

The invention discloses treatment of acute myelogenous leukemia (AML) characterized by a mutant allele of IDH1 using COMPOUND 2, or a pharmaceutically acceptable salt thereof, alongside induction and consolidation therapy. The induction regimen comprises cytarabine and an anthracycline selected from daunorubicin and idarubicin, followed by consolidation therapy with cytarabine. COMPOUND 2 is administered during both induction and consolidation phases, and the specified IDH1 mutations are R132H, R132C, R132L, R132V, R132S, and R132GF.

The description also discloses crystalline Forms 1 and 2 of COMPOUND 2 and an amorphous solid dispersion, which are described as capable of improving aqueous solubility and oral exposure compared with crystalline material. Additionally, a Phase 1 study in IDH1-mutant AML assesses safety, pharmacokinetics, 2-hydroxyglutarate pharmacodynamics, and clinical response without reported results. The problem being solved is not explicitly described in patent.

Claims Coverage

The supplied claims identify one independent claim. Its coverage is summarized in three inventive features; dependent claims are described as refining doses, induction schedules, treatment details, and AML subtypes.

Treatment of IDH1-mutant acute myelogenous leukemia

The independent claim covers treating acute myelogenous leukemia characterized by a mutant allele of IDH1 selected from R132H, R132C, R132L, R132V, R132S, and R132GF with COMPOUND 2 or a pharmaceutically acceptable salt thereof.

Induction therapy regimen

The claim specifies an induction therapy regimen consisting of cytarabine and an anthracycline selected from daunorubicin and idarubicin.

Consolidation therapy regimen and COMPOUND 2 administration

The claim specifies a consolidation therapy regimen consisting of cytarabine and provides that COMPOUND 2 is administered during both induction and consolidation.

The independent claim combines treatment of specified IDH1-mutant AML using COMPOUND 2 with cytarabine-based induction and consolidation regimens, with COMPOUND 2 administered during both phases.

Stated Advantages

The crystalline forms and amorphous solid dispersion of COMPOUND 2 are described as capable of improving aqueous solubility and oral exposure compared with crystalline material.

Documented Applications

Treatment of acute myelogenous leukemia characterized by specified IDH1 R132 mutations, using COMPOUND 2 alongside induction and consolidation therapy.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.